BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 30415451)

  • 21. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Kvamme MK; Kristiansen IS; Lie E; Kvien TK
    J Rheumatol; 2010 Jan; 37(1):26-31. PubMed ID: 19955045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
    Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
    Haberhauer G; Strehblow C; Fasching P
    Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].
    Anić B; Babić-Naglić Ð; Grazio S; Kehler T; Kaliterna DM; Radoncić KM; Morović-Vergles J; Novak S; Prus V; Vlak T; Baresić M
    Reumatizam; 2015; 62(1):12-9. PubMed ID: 27024887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE; Kay J; Wasko MC; Keystone E; Kavanaugh A; Deodhar A; Murphy FT; Magnus JH; Hsia EC; Hsu B; Xu S; Rahman MU; Doyle MK
    Rheumatology (Oxford); 2013 Oct; 52(10):1845-55. PubMed ID: 23838027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
    Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study.
    Miler M; Nikolac Gabaj N; Grazio S; Vahtarić A; Vrtarić A; Grubišić F; Skala Kavanagh H; Doko Vajdić I; Vrkić N
    Rheumatol Int; 2020 Sep; 40(9):1455-1461. PubMed ID: 32462255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV
    Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
    Front Immunol; 2021; 12():631603. PubMed ID: 34177886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
    Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
    Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
    Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
    Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
    Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
    BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
    Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.